A Deloitte and Thomson Reuters study released today found that drugmakers continue to struggle to improve returns on research and development despite an increasing number of new drug approvals. Estimated returns on investment in Phase III drug research and development fell from 2010’s 10.5% and 2012’s 7.2% to 4.8% this year. The average cost of developing new drugs increased by 18% to $1.3 billion from 2010 to 2013, according to the report.
